Remote patient monitoring is booming in Medicare. The evidence lags the billing

Remote patient monitoring — where a patient uses a connected device at home, such as a blood-pressure cuff or a glucose meter, and a clinical team is paid to review the data — has grown into a large Medicare line item faster than the evidence for it has matured. Medicare paid more than $500 million for remote monitoring in 2024, yet a federal watchdog found that 43% of enrollees receiving it did not get all the components the service is supposed to include, and high-quality evidence that it improves outcomes remains limited outside a few conditions [s1][s2].

The growth is real and rapid

The scale of the shift is not in dispute. A study in JAMA Internal Medicine documented that general remote patient monitoring in traditional Medicare rose sharply between early 2018 and late 2021 [s3]. The federal Office of Inspector General found the same trajectory continuing, reporting that use increased dramatically from 2019 to 2022, and its later review put Medicare payments for the service above $500 million in 2024 [s1][s2]. Billing codes introduced to reimburse device setup, data supply and monthly management turned home monitoring into a repeatable revenue stream, and clinics responded.

What the watchdog found

Growth is not the same as value, and the inspector general's concern is that a good deal of the billing may not reflect the service patients are supposed to get. Remote monitoring, as Medicare defines it, has three parts: educating and setting up the patient with the device, supplying the device and collecting data, and a clinician reviewing that data and managing treatment. The review found that about 43% of enrollees who received remote monitoring did not receive all three components — meaning, in many cases, a patient was billed for monitoring without the full loop of device, data and clinical action that makes monitoring useful [s1].

The oversight gaps compound the problem. Medicare, the inspector general noted, lacks basic information for policing the service, including who ordered the monitoring, and both the OIG and the Centers for Medicare & Medicaid Services have flagged fraud risk in the category [s1]. When a service can be billed monthly and the payer cannot easily see whether the clinical work happened, the incentive structure runs ahead of the evidence.

The billing structure itself explains part of the surge. Separate codes reimburse the initial device setup and patient education, the supply of the device and transmission of data, and the monthly treatment-management time a clinician spends reviewing it — a recurring, per-patient revenue stream that rewards enrolling and retaining patients on monitoring [s1]. That design is not inherently wrong; it is how any ongoing service gets paid. But it means the volume of billing can rise for reasons — enrolment and retention — that are only loosely tied to whether patients are getting better, which is exactly why the inspector general's finding that a large share of enrollees never received the full three-part service is so pointed [s1].

Where the evidence is strongest — and where it thins

Remote monitoring is not uniformly unproven; it varies sharply by what is being monitored. Its best-evidenced use is self-measured blood pressure with clinician review, which aligns with the broader finding that out-of-office blood-pressure readings predict risk better than clinic measurements and are what guidelines now require to confirm a diagnosis. For that specific task, home data feeding back to a clinician has a real rationale.

The weaker end is everything sold as generic "monitoring" — passive data collection across chronic conditions where no trial has shown that watching the numbers changes what happens to the patient. The same limitation constrains the whole home-monitoring field: a stream of readings is only as valuable as the clinical response attached to it, which is exactly what the 43% figure suggests is often missing [s1]. This is the acute-care cousin of hospital-at-home, where the evidence supports equivalent safety at lower cost rather than better outcomes, and it shares the dependence on real clinical follow-up seen with connected inhalers.

What this means for a reader

Remote patient monitoring can be genuinely useful when it is the right measurement, feeding a clinician who acts on it — self-measured blood pressure is the clearest case [s1]. But its explosive growth in Medicare has outpaced both the evidence and the oversight, and a large share of billed monitoring appears not to deliver the full service [s1][s2]. For a patient offered a home-monitoring programme, the questions that separate value from billing are simple: what exactly is being measured, who reviews it, and what will change based on the readings. If the answer to the last two is vague, the monitoring is likely generating a claim more than it is improving care.

Sources

• [s1] HHS Office of Inspector General — Additional Oversight of Remote Patient Monitoring in Medicare Is Needed (OEI-02-23-00260) (2024-09-19)
• [s2] HHS Office of Inspector General — Billing for Remote Patient Monitoring (OEI-02-23-00261) (2025-08-25)
• [s3] JAMA Internal Medicine — Trends in Remote Patient Monitoring Use in Traditional Medicare (2022-09-01)